search
Back to results

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Primary Purpose

Allogeneic Hematopoietic Stem Cell Transplantation

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Vancomycin Pre-Treatment
Vancomycin Placebo
SER-155
SER-155 Placebo
Sponsored by
Seres Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Allogeneic Hematopoietic Stem Cell Transplantation focused on measuring Microbiome, stem cell transplant

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female subjects ≥ 18 years of age undergoing HSCT.
  • Planning to undergo allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen matched sibling, haploidentical related donor, HLA-matched unrelated donor, or HLA 1-antigen mismatched unrelated donor, with either bone marrow or peripheral blood stem cells as a graft source, and with any conditioning regimen

Exclusion Criteria:

  • Severe colitis of any etiology or active/currently-treated inflammatory bowel disease (IBD) or total colectomy.
  • Evidence of relapse or progression of hematologic malignancy (minimal residual disease is allowed).
  • Transplant using umbilical cord blood or ex vivo T-cell-depleted HSCT
  • Receipt of chimeric antigen receptor T-cell (CAR-T) therapy.
  • Received a fecal microbiota transplant (FMT) or any live microbial therapeutic within 3 months prior to Screening.
  • Known allergy or intolerance to oral vancomycin.
  • Concomitant participation or participation within 14 days or 5 half-lives of another investigational unapproved treatment, whichever is longer.

Sites / Locations

  • Banner Health - MD Anderson Medical Center
  • Mayo Clinic - ScottsdaleRecruiting
  • University of California, Los Angeles - Division of Hematology-Oncology
  • University of Florida - Division of Hematology & OncologyRecruiting
  • Mayo Clinic - JacksonvilleRecruiting
  • University of Chicago Medical CenterRecruiting
  • Harvard Medical School - Massachusetts General Hospital Cancer CenterRecruiting
  • Mayo Clinic - Rochester
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • University of North Carolina Chapel Hill
  • University Hospitals Cleveland Medical Center
  • The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center
  • Fred Hutchinson Cancer Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1 - Open Label Study

Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study

Arm Description

Vancomycin & SER-155

Vancomycin & SER-155 OR Vancomycin placebo & SER-155 placebo

Outcomes

Primary Outcome Measures

Safety and tolerability of SER-155, including incidence and severity of adverse events, serious adverse events, or adverse events of special interest
Incidence and severity of participants with adverse events, serious adverse events, or adverse events of special interest
Engraftment of SER-155
Prevalence of SER-155 strains in subject stool measured before and after treatment courses

Secondary Outcome Measures

Abundance of Enterococcus and Enterobacteriaceae
Combined and individual incidence of bloodstream infections, gastrointestinal infections, and acute Graft-versus Host Disease
Incidence and duration of febrile neutropenia

Full Information

First Posted
July 13, 2021
Last Updated
August 3, 2023
Sponsor
Seres Therapeutics, Inc.
Collaborators
Memorial Sloan Kettering Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04995653
Brief Title
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Official Title
A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 24, 2021 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Seres Therapeutics, Inc.
Collaborators
Memorial Sloan Kettering Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Detailed Description
This is a Phase 1b randomized, double-blind, placebo-controlled, multiple dose, multicenter study designed to evaluate the safety, efficacy, and microbiome alterations associated with SER-155 dosing, after microbiome conditioning with oral vancomycin, in adult subjects aged ≥18 years who are undergoing Hematopoietic Stem Cell Transplantation (HSCT).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Allogeneic Hematopoietic Stem Cell Transplantation
Keywords
Microbiome, stem cell transplant

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
There are 2 parts or cohorts for the trial. Cohort 1 is an open-label study. Cohort 2 is double-blind, randomized, placebo-controlled study.
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1 - Open Label Study
Arm Type
Experimental
Arm Description
Vancomycin & SER-155
Arm Title
Cohort 2 - Randomized, Double-Blind, Placebo-Controlled Study
Arm Type
Experimental
Arm Description
Vancomycin & SER-155 OR Vancomycin placebo & SER-155 placebo
Intervention Type
Drug
Intervention Name(s)
Vancomycin Pre-Treatment
Intervention Description
Four times daily dosing with Vancomycin
Intervention Type
Drug
Intervention Name(s)
Vancomycin Placebo
Intervention Description
Four times daily dosing with Vancomycin Placebo
Intervention Type
Drug
Intervention Name(s)
SER-155
Intervention Description
Once daily dosing with SER-155
Intervention Type
Drug
Intervention Name(s)
SER-155 Placebo
Intervention Description
Once daily dosing with SER-155 placebo
Primary Outcome Measure Information:
Title
Safety and tolerability of SER-155, including incidence and severity of adverse events, serious adverse events, or adverse events of special interest
Description
Incidence and severity of participants with adverse events, serious adverse events, or adverse events of special interest
Time Frame
Day 100
Title
Engraftment of SER-155
Description
Prevalence of SER-155 strains in subject stool measured before and after treatment courses
Time Frame
Day 100
Secondary Outcome Measure Information:
Title
Abundance of Enterococcus and Enterobacteriaceae
Time Frame
Day 100
Title
Combined and individual incidence of bloodstream infections, gastrointestinal infections, and acute Graft-versus Host Disease
Time Frame
Day 100
Title
Incidence and duration of febrile neutropenia
Time Frame
Day 100

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female subjects ≥ 18 years of age undergoing HSCT. Planning to undergo allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen matched related donor, haploidentical related donor, HLA-matched unrelated donor, or HLA 1-antigen mismatched unrelated or related donor, with either bone marrow or peripheral blood stem cells as a graft source, and with any conditioning regimen Exclusion Criteria: Severe colitis of any etiology or active/currently-treated inflammatory bowel disease (IBD) or total colectomy. Evidence of relapse or progression of hematologic malignancy (minimal residual disease is allowed). Transplant using umbilical cord blood or ex vivo T-cell-depleted HSCT Receipt of chimeric antigen receptor T-cell (CAR-T) therapy. Received a fecal microbiota transplant (FMT) or any live microbial therapeutic within 3 months prior to Screening. Known allergy or intolerance to oral vancomycin. Concomitant participation or participation within 14 days or 5 half-lives of another investigational unapproved treatment, whichever is longer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bina Tejura, MD
Phone
617-945-9626
Email
clinicalstudies@serestherapeutics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doris Ponce, MD
Organizational Affiliation
MSKCC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bina Tejura, MD
Organizational Affiliation
Seres Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Banner Health - MD Anderson Medical Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Mayo Clinic - Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
University of California, Los Angeles - Division of Hematology-Oncology
City
Marina Del Rey
State/Province
California
ZIP/Postal Code
90292
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
University of Florida - Division of Hematology & Oncology
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Mayo Clinic - Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Harvard Medical School - Massachusetts General Hospital Cancer Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Mayo Clinic - Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
University of North Carolina Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27514
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
University Hospitals Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
The Pennsylvania State University (Penn State) Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Investigator Site

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

We'll reach out to this number within 24 hrs